With $100 million in Series B financing, regRNA-targeting drug developer plans platform expansion, start of clinical trials for lead candidates
CAMP4 Therapeutics specializes in treatments that target regRNAs, forms of RNA that regulate the expression of nearby protein-encoding genes, and have not been explored as therapeutic targets. The company’s RNA Actuating Platform (RAP™) is designed to map regRNAs associated with every protein-coding gene in any cell type, while the programmable antisense oligonucleotide (ASO) therapeutics developed through the platform target the controlling regRNAs to upregulate gene expression to treat disease. [Suite Four Photography / Acadia Mezzofanti]
CAMP4 specializes in treatments that target regRNAs, forms of RNA that regulate the expression of nearby protein-encoding genes and have not been explored as therapeutic targets. RegRNAs are within what scientists often call the “dark side” of the genome— the 98% of the human genome that does not encode proteins . . .
